Last reviewed · How we verify
AZD2115 Dose 1
AZD2115 is an investigational drug with an undisclosed mechanism of action.
At a glance
| Generic name | AZD2115 Dose 1 |
|---|---|
| Sponsor | Pearl Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The specific mechanism of action for AZD2115 has not been publicly disclosed, making it difficult to provide detailed information about its biological effects.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD (PHASE2)
- AZD2115 Multiple Ascending Dose Study (PHASE1)
- AZD2115 Single Ascending Dose Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2115 Dose 1 CI brief — competitive landscape report
- AZD2115 Dose 1 updates RSS · CI watch RSS
- Pearl Therapeutics, Inc. portfolio CI